Adverse prognostic impact of CD36 and CD2 expression in adult de novo acute myeloid leukemia patients.

[1]  M. Minden,et al.  Prognostic relevance of immunophenotyping in 379 patients with acute myeloid leukemia. , 2004, Leukemia research.

[2]  H. Cavé,et al.  Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program , 2003, Leukemia.

[3]  D. Linch,et al.  Flt3 mutations and leukaemia , 2003, British journal of haematology.

[4]  H. Dombret,et al.  Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup. , 2003, Blood.

[5]  G Valet,et al.  Pretherapeutic identification of high‐risk acute myeloid leukemia (AML) patients from immunophenotypic, cytogenetic, and clinical parameters , 2003, Cytometry. Part B, Clinical cytometry.

[6]  G. Ehninger,et al.  Immunophenotyping is an independent factor for risk stratification in AML , 2003, Cytometry. Part B, Clinical cytometry.

[7]  G. Laurent,et al.  Macrophage recognition and phagocytosis of apoptotic fibroblasts is critically dependent on fibroblast-derived thrombospondin 1 and CD36. , 2003, The American journal of pathology.

[8]  V. Deneys,et al.  Immunological classification of acute myeloblastic leukemias: relevance to patient outcome , 2003, Leukemia.

[9]  N. Villamor,et al.  Acute myeloid leukemia with MLL rearrangements: clinicobiological features, prognostic impact and value of flow cytometry in the detection of residual leukemic cells , 2003, Leukemia.

[10]  N. Villamor,et al.  Immunophenotypic findings in acute myeloid leukemia with FLT3 internal tandem duplication. , 2003, Haematologica.

[11]  A. Goldstone,et al.  The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial , 2002, British journal of haematology.

[12]  H. Gundacker,et al.  Impact of trisomy 8 (+8) on clinical presentation, treatment response, and survival in acute myeloid leukemia: a Southwest Oncology Group study. , 2002, Blood.

[13]  N. Testoni,et al.  CD56 antigenic expression in acute myeloid leukemia identifies patients with poor clinical prognosis , 2001, Leukemia.

[14]  M. Caligiuri,et al.  Expression profiling reveals fundamental biological differences in acute myeloid leukemia with isolated trisomy 8 and normal cytogenetics. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[15]  A. Aventín,et al.  Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies. , 2001, Haematologica.

[16]  M. Slovak,et al.  Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study , 2000 .

[17]  S. Hiebert,et al.  The inv(16) encodes an acute myeloid leukemia 1 transcriptional corepressor. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[18]  A. Órfão,et al.  An abnormal CD34+ myeloid/CD34+ lymphoid ratio at the end of chemotherapy predicts relapse in patients with acute myeloid leukemia. , 1999, Cytometry.

[19]  A Orfao,et al.  Impact of immunophenotyping on management of acute leukemias. , 1999, Haematologica.

[20]  K Wheatley,et al.  The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. , 1998, Blood.

[21]  Marcos González,et al.  Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients , 1997 .

[22]  H. Saito,et al.  CD7+ and CD56+ myeloid/natural killer cell precursor acute leukemia: a distinct hematolymphoid disease entity. , 1997, Blood.

[23]  H. Yamasaki,et al.  Myelomonoblastic leukaemia cells carrying the PEBP2β/MYH11 fusion gene are CD34+, c‐KIT+ immature cells , 1997, British journal of haematology.

[24]  H. Sather,et al.  CD2 antigen expression on leukemic cells as a predictor of event-free survival after chemotherapy for T-lineage acute lymphoblastic leukemia: a Children's Cancer Group study , 1996 .

[25]  H. Kaneko,et al.  Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. , 1996, Leukemia.

[26]  A. Armesilla,et al.  Structural and Functional Characterization of the Human CD36 Gene Promoter , 1996, The Journal of Biological Chemistry.

[27]  A Orfao,et al.  Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). , 1995, Leukemia.

[28]  G. Masera,et al.  CD2 expression in acute promyelocytic leukemia is associated with microgranular morphology (FAB M3v) but not with any PML gene breakpoint. , 1995, Leukemia.

[29]  A. Órfão,et al.  Gene rearrangement in acute non‐lymphoblastic leukaemia: correlation with morphological and immunophenotypic characteristics of blast cells , 1995, British journal of haematology.

[30]  A. Armesilla,et al.  Structural organization of the gene for human CD36 glycoprotein. , 1994, The Journal of biological chemistry.

[31]  N. Mahmud,et al.  Expression of MDR1 gene in acute leukemia cells: association with CD7+ acute myeloblastic leukemia/acute lymphoblastic leukemia. , 1993, Blood.

[32]  J. Yunis,et al.  Acute myeloid leukemia M4 with inv(16) (p13q22) exhibits a specific immunophenotype with CD2 expression [letter] , 1993 .

[33]  A. Hagemeijer,et al.  Acute myeloid leukemia M4 with bone marrow eosinophilia (M4Eo) and inv(16)(p13q22) exhibits a specific immunophenotype with CD2 expression. , 1993, Blood.

[34]  H. Tilly,et al.  CD2+ CD19+ acute lymphoblastic leukaemia in 16 children and adults: clinical and biological features. The Groupe d'Etude Immunologique des Leucémies (G.E.I.L.) , 1993, British journal of haematology.

[35]  H. Ikeda,et al.  Membrane glycoprotein CD36: a review of its roles in adherence, signal transduction, and transfusion medicine. , 1992, Blood.

[36]  E. Estey,et al.  Correlation of CD2 expression with PML gene breakpoints in patients with acute promyelocytic leukemia. , 1992, Blood.

[37]  J. V. van Dongen,et al.  Immunoglobulin and T-cell receptor gene rearrangements in acute non-lymphocytic leukemias. Analysis of 54 cases and a review of the literature. , 1991, Leukemia.

[38]  S. Piantadosi,et al.  Prognostic importance of immunophenotyping in adults with acute myelocytic leukaemia: the significance of the stem‐cell glycoprotein CD34 (My 10) , 1990, British journal of haematology.

[39]  C. Bloomfield,et al.  Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  D. H. Mellor,et al.  Real time , 1981 .

[41]  Iscn.  International System for Human Cytogenetic Nomenclature , 1978 .